Fujifilm Diosynth Biotechnologies
WuXi NextCODE has raised $240 million in series B, FDA slapped Celltrion with a long Form 483, Biocon's $275 million insulin plant opened shop.
Japan's Fujifilm Diosynth Biotechnologies has completed a $9 million expansion project of its cell manufacturing facilities in the U.K.
Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge discounts.
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
Novartis' CEO said China's pharma market will surpass $300 billion by 2020, Hanmi failed to report olmutinib side effect on time, Celgene tapped first Asia-Pacific partner.
Fujifilm is investing about $130 million in its U.S. and U.K. plants to increase biologics manufacturing as it races to capture a piece of the growing business.